

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 071949-5301	SERIAL NO. 09/835,298
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION Submitted on July 10, 2002 (Use several sheets if necessary)		APPLICANT: Jeffrey R. Dahlen et al.		
		FILING DATE: 04/13/2001	GROUP ART UNIT: 1614 (64)	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
<i>jl</i>	A1	5,580,722	12-03-1996	Foulkes et al.	435	6	
<i>jl</i>	A2	5,786,163	07-28-1998	Hall	435	7.92	
<i>jl</i>	A3	6,117,644	09-12-2000	DeBold	435	7.1	
<i>jl</i>	A4						
<i>jl</i>	A5						
<i>jl</i>	A6						
<i>jl</i>	A7						

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO
<i>jl</i>	B1	WO 91/09627	07-11-1991	Hedner et al.			
	B2						
	B3						
	B4						


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	International Search Report in PCT Application No. PCT/US02/11441 dated 9 July 2002
	C2	
	C3	
	C4	
	C5	

EXAMINER	DATE CONSIDERED
<i>JR</i>	7/28/05

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

RECEIVED
TECH CENTER 1600/2900
JUL 17 2002



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO TRADEMARK

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: January 20, 2005

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/835,298
Date Submitted: January 20, 2005		Filing Date	04/13/2001
(use as many sheets as necessary)		First Named Inventor	DAHLEN et al.
		Group Art Unit	1641 1641
		Examiner Name	Gabel
Sheet	1	Attorney Docket Number	071949-5301

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
OG	A1	5786163		Hall	07-28-1998	
OG	A2	6627457		Pandian et al.	09-30-2003	
OG	A3	6670138		Gonzalez-Zulueta et al.	12-30-2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
OG	A4	Huttunen et al., "Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. The Journal of Biological Chemistry, 275:40096-40105, 2000.	
	A5	Mussack et al., Early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated severe head trauma: a comparative pilot study on common pathomechanisms. Resuscitation, 49:193-199, 2001.	
	A6	Yakovlev et al., Activation of CPP32-Like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. The Journal of Neuroscience, 17(19): 7415-724, 1997.	
	A7	International Search Report for international application No. PCT/US04/26984	
	A8	Notice of References Cited, PTO-892, Part of Paper No. 20041202 from U.S. Application No. 10/225,082 filed August 20, 2002.	

Examiner Signature		Date Considered	7/25/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/P-10

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: December 7, 2001

(use as many sheets as necessary)

Sheet 1 of 7

Complete if Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	Jeffrey R. Dahlen et al.
Group Art Unit	1614 (64.)
Examiner Name	
Attorney Docket Number	071949-5301

DEC 28 2001
CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
<i>Qil</i>	A1	5,480,792	US A	Buechler et al.	01-02-1996	
	A2	5,525,524	US A	Buechler et al.	06-11-1996	
	A3	5,631,171	US A	Sandstrom et al.	05-20-1997	
	A4	5,679,526	US A	Buechler et al.	10-21-1997	
	A5	5,795,725	US A	Buechler et al.	08-18-1998	
	A6	5,824,799	US A	Buechler et al.	10-20-1998	
	A7	5,851,776	US A	Valkirs	12-22-1998	
	A8	5,885,527	US A	Buechler	03-23-1999	
	A9	5,922,615	US A	Nowakowski et al.	07-13-1999	
	A10	5,939,272	US A	Buechler et al.	08-17-1999	
	A11	5,947,124	US A	Buechler et al.	09-07-1999	
	A12	5,955,377	US A	Maul et al.	09-21-1999	
	A13	5,985,579	US A	Buechler et al.	11-16-1999	
	A14	6,019,944	US A	Buechler	02-01-2000	
	A15	6,113,855	US A	Buechler	09-05-2000	
	A16	6,143,576	US A	Buechler	11-07-2000	
	A17	6,147,688	US A	Clair	11-14-2000	
	A18	6,156,521	US A	Buechler et al.	12-05-2000	

FOREIGN PATENT DOCUMENTS

Examiner
Signature

John


Date
Considered

7/25/05

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1469 (08-01)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: December 7, 2001

(use as many sheets as necessary)

Sheet 2 of 7

Complete If Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	Jeffrey R. Dahlen et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	071949-5301

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
DEC 16 2002
2001

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>DR</i>	A19	ALEXANDER et al., "30-Day and 6-Month Mortality in Proportional to Magnitude of Peak Creatine Kinase Elevation in the Non-ST-elevation Acute Coronary Syndromes," Circulation (Supp.), 1998, p. I-629.	
	A20	ANTMAN et al., "Cardiac-Specific Troponin I Levels to Predict the Risk of Mortality in Patients with Acute Coronary Syndromes," The New England Journal of Medicine, 1996, p. 1342-49, Vol. 335, No. 18.	
	A21	ANTMAN et al., "Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction," Circulation, 1999, p. 1593-1601, Vol. 100.	
	A22	ARAKAWA et al., "Relationship Between Plasma Level of Brain Natriuretic Peptide and Myocardial Infarct Size," Cardiology, 1994, p. 334-340, Vol. 85.	
	A23	ARAKAWA et al., "Plasma Brain Natriuretic Peptide Concentrations Predict Survival After Acute Myocardial Infarction," JACC, June 1996, p. 1656-61, Vol. 27, No. 7.	
	A24	BERGER et al., "B-Type Natriuretic Peptides (BNP and PRO-BNP) Predict Longterm Survival in Patients with Advanced Heart Failure Treated with Atenolol," Journal of the Heart and Lung Transplantation, 2001, p. 251, Vol. 20, No. 2.	
	A25	BRAUNWALD et al., "Unstable Angina: Diagnosis and Management," Clinical Practice Guideline No. 10 (amended), AHCPR Publication No. 94-0602, Rockville, MD: Department of Health and Human Services, 1994.	
	A26	CANNON et al., "Invasive Versus Conservative Strategies in Unstable Angina and Non-Q-Wave Myocardial Infarction Following Treatment with Tirofiban: Rationale and Study Design of the International TACTICS-TIMI 18 Trial," Am. J. Cardiology, 1998, p. 731-736, Vol. 82.	
	A27	CANNON et al., "Oral Glycoprotein IIb/IIIa Inhibition with Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) Trial," Circulation, 2000, p. 149-156, Vol. 102.	
	A28	CHENG et al., "A Rapid Bedside Test for B-Type Peptide Predicts Treatment Outcomes in Patients Admitted for Decompensated Heart Failure: A pilot Study," Journal of the American College of Cardiology, 2001, p. 386-391, Vol. 37, No. 2.	
<i>DR</i>	A29	DAO et al., "Utility of B-Type Natriuretic Peptide in the Diagnosis of Congestive Heart Failure in an Urgent-Care Setting," Journal of the American College of Cardiology, 2001, p. 379-385, Vol. 37, No. 2.	

Examiner Signature	<i>A. Dahlen</i>	Date Considered	7/25/05
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/773 TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: December 7, 2001

(use as many sheets as necessary)

Sheet

3

of

7

Complete if Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	Jeffrey R. Dahlen et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	071949-5301

RECEIVED
U.S. Patent and Trademark Office
ENTERED 16001600
10062000
10062000

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>DR</i>	A30	DARBAR et al., "Diagnostic Value of B-Type Natriuretic Peptide Concentrations in Patients with Acute Myocardial Infarction," Am. J. Cardiology, 1996, p. 284-287, Vol. 78.	
<i>DR</i>	A31	FISCHER et al., "Evaluation of a New, Rapid Bedside Test for..." Clinical Chemistry, 2001, p. 591-594, Vol. 47, No. 3.	
	A32	GRAYBURN et al., "Perfluenapent Emulsion (EchoGen®): A New Long-Acting Phase-Shift Agent for Contrast Echocardiography," Clinical Cardiology, 1997, p. I-12 – I-18, Vol. 20 (Supp I).	
	A33	HAMA et al., "Rapid Ventricular Induction of Brain Natriuretic Peptide Gene Expression in Experimental Acute Myocardial Infarction," Circulation, 1995, p. 1558-1564, Vol. 92.	
	A34	HAMM et al., "Benefit of Abciximab in Patients with refractory Unstable Angina in Relation to serum Troponin T Levels," New England Journal of Medicine, 1999, p. 1623-1629, Vol. 340, No. 21.	
	A35	HORIO et al., "Serial Changes in Atrial and Brain Natriuretic Peptides in Patients with Acute Myocardial Infarction Treated with early Coronary Angioplasty," American Heart Journal, 1993, p. 293-299, Vol. 126.	
	A36	HUNT et al., "The Amino-Terminal Portion of Pro-Brain Natriuretic Peptide (Pro-BNP) Circulates in Human Plasma," Biochemical and Biophysical Research Communications, 1995, p. 1175-1183, Vol. 214, No. 3.	
<i>DR</i>	A37	KIKUTA et al., "Increased Plasma Levels of B-Type Natriuretic Peptide in Patients with Unstable Angina," American Heart Journal, 1996, p. 101-107, Vol. 132, No. 1.	


Examiner Signature	<i>DR</i>	Date Considered	<i>7/25/05</i>
--------------------	-----------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449 TRADEMARK

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: December 7, 2001

(use as many sheets as necessary)

Sheet 4 of 7

Complete if Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	Jeffrey R. Dahlen et al.
Group Art Unit	1614
Examiner Name	

Attorney Docket Number 071949-5301

RECEIVED
U.S. PATENT & TRADEMARK OFFICE
DEC 28 2001
160/2001

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>CD</i>	A38	KLOOTWIJK et al., "Acute Coronary Syndromes: Diagnosis," The Lancet, June 1999, p. 1109-1113, Vol. 132.	
	A39	KYRIAKIDES et al., "Brain Natriuretic Peptide Increases Acutely and Much More Prominently than Atrial Natriuretic Peptide during Coronary Angioplasty," Clinical Cardiology, 2000, p. 285-288, Vol. 23.	
	A40	LLOYD-JONES et al., "Electrocardiographic and Clinical Predictors of Acute Myocardial Infarction in Patients with Unstable Angina Pectoris," Am. J. Cardiology, 1998, p. 1182-1186, Vol. 81.	
	A41	MARUMOTO et al., "Increased Secretion of Atrial and Brain Natriuretic Peptides During Acute Myocardial Ischaemia Induced by Dynamic Exercise in Patients with Angina Pectoris," Clinical Science, 1995, p. 551-556, Vol. 88.	
	A42	MORROW et al., "C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy," JACC, June 1998, p. 1460-5, Vol. 31, No. 7.	
	A43	MORROW ET AL., "Cardiac Troponin I for Stratification of early Outcomes and the efficacy of Enoxaparin in Unstable Angina: A TIMI-11B Substudy," JACC, 2000, p. 1812-1817, Vol. 36, No. 6.	
	A44	MOTWANI et al., "Plasma Brain Natriuretic Peptide as an Indicator for Angiotensin-converting-enzyme Inhibition After Myocardial Infarction," The Lancet, 1993, p. 1109-13, Vol. 341.	
<i>CD</i>	A45	NAGAYA et al., "Plasma Brain Natriuretic Peptide is a Biochemical Marker for the Prediction of Progressive Ventricular Remodeling after Acute Myocardial Infarction," American heart Journal, 1998, p. 21-8, Vol. 135.	

Examiner Signature

A handwritten signature in black ink, appearing to read "Jeffrey R. Dahlen".

Date Considered


1/25/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: December 7, 2001

(use as many sheets as necessary)

Sheet 5 of 7

Complete if Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	Jeffrey R. Dahlen et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	071949-5301

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>Al</i>	A46	NYMAN et al., "Very Early Risk Stratification by Electrocardiogram at Rest in Men with Suspected Unstable Coronary Heart Disease," Journal of Internal Medicine, 1993, p. 293-301, Vol. 234.	
	A47	OMLAND et al., "Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival After Acute Myocardial Infarction," Circulation, 1996, p. 1063-1069, Vol. 93.	
	A48	OMLAND et al., "Plasma Cardiac Natriuretic Peptide Determination as a Screening Test for the Detection of Patients with Mild Left Ventricular Impairment," Heart, 1996, p. 232-237, Vol. 76.	
	A49	PATEL et al., "Early Continuous ST Segment Monitoring in Unstable Angina: Prognostic Value Additional to the Clinical Characteristics and the Admission Electrocardiogram," Heart, 1996, p. 222-228, Vol. 75.	
	A50	PATEL et al., "The Importance of Early Risk Stratification Using Continuous ST Segment Monitoring," European Heart Journal, 1998, p. 240-249, Vol. 19.	
	A51	RICHARDS et al., "Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin," Circulation, 1998, p. 1921-1929, Vol. 97.	
	A52	RICHARDS et al., "Neuroendocrine Prediction of Left Ventricular Function and Heart Failure After Acute Myocardial Infarction," Heart, 1999, p. 114-120, Vol. 81.	
<i>Al</i>	A53	RIDKER et al., "Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels," Circulation, 1998, p. 839-844, Vol. 98.	

Examiner Signature

Date Considered

1/25/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	09/835,298	
Date Submitted: December 7, 2001 (use as many sheets as necessary)			Filing Date	04/13/2001	
6 of 7			First Named Inventor	Jeffrey R. Dahlen et al.	
			Group Art Unit	1614	
			Examiner Name		
			Attorney Docket Number	071949-5301	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>JD</i>	A54	SAVONITTO et al., "Prognostic Value of the Admission Electrocardiogram in Acute Coronary Syndromes," JAMA, 1999, p. 707-713, Vol. 281.	
	A55	STEIN et al., "Natriuretic Peptides: Physiology, Therapeutic Potential, and Risk Stratification in Ischemic Heart Disease," American heart Journal, 1998, p. 914-923, Vol. 135.	
	A56	TALWAR et al., "Profile of Plasma N-terminal proBNP Following Acute Myocardial Infarction," European Heart Journal, 2000, p. 1514-1521, Vol. 21.	
	A57	TALWAR et al., "Plasma N-terminal Pro-Brain Natriuretic Peptide and Cardiotrophin 1 are raised in Unstable Angina," Heart, 2000, p. 421-424, Vol. 84.	
	A58	TATEISHI et al., "Transient Increase in Plasma Brain (B-Type) Natriuretic Peptide After Percutaneous Transluminal Coronary Angioplasty," Clinical Cardiology, 2000, p. 776-780, Vol. 23.	
	A59	TATEYAMA et al., "Concentrations and Molecular Forms of Human Brain Natriuretic Peptide in Plasma," Biochemical and Biophysical Research Communications, 1992, p. 760-767, Vol. 185, No. 2.	
	A60	THEROUX et al., "Acute Coronary Syndromes," Circulation, 1998, p. 1195-1206, Vol. 97.	
<i>JD</i>	A61	TROUGHTON et al., "Treatment of Heart Failure Guided by Plasma Aminoterminal Brain Natriuretic Peptide (N-BNP) Concentrations," The Lancet, 2000, p. 1126-1130, Vol. 355.	

Examiner Signature	<i>Jeffrey R. Dahlen</i>	Date Considered	<i>7/25/05</i>
--------------------	--------------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: December 7, 2001

(use as many sheets as necessary)

Sheet 7 of 7

Complete if Known

Application Number 09/835,298

Filing Date 04/13/2001

First Named Inventor Jeffrey R. Dahlen et al.

Group Art Unit 1614

Examiner Name

Attorney Docket Number 071949-5301

DEC 28 2001
U.S. PATENT AND TRADEMARK OFFICE
RECEIVED
CH

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>de</i>	A62	VAN VELDHUISEN et al., "High Versus Low Dose ACE Inhibition in Chronic Heart Failure," JACC, 1998, p. 1811-1818, Vol. 32, No. 7.	
	A63	WEISE et al., "Gene Expression of Brain Natriuretic Peptide in Isolated Atrial and Ventricular Human Myocardium," Circulation, 2000, p. 3074-3079, Vol. 102.	
	A64	YASUE et al., "Localization and Mechanism of Secretion of B-Type Natriuretic Peptide in Comparison with Those of A-Type Natriuretic Peptide in Normal Subjects and Patients with Heart failure," Circulation, 1998, p. 195-203, Vol. 90.	
	A65	YOSHIMURA et al., "Different Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients with Congestive Heart Failure," Circulation, 1993, p. 464-469, Vol. 87.	
<i>✓</i>	A66	YUSUF et al., "Variations Between Countries in Invasive Cardiac Procedures and Outcomes in Patients with Suspected Unstable Angina or Myocardial Infarction without Initial ST Elevation," The Lancet, 1998, p. 507-514, Vol. 352.	

Examiner Signature

DeYar

Date Considered

7/25/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.